Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 291
Filtrar
1.
Afr Health Sci ; 24(1): 198-205, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-38962344

RESUMEN

Background: There is limited published data regarding the distribution of esophageal cancer patients by sub-regions, districts and ethnicity in Uganda. Objectives: To study the distribution by sub-regions, districts, ethnicity and sub-regions post-care outcomes of esophageal cancer patients in care over ten years at the Uganda Cancer Institute. Methods: Patients' charts with confirmed diagnoses of esophageal cancer for 2009-2019 were identified. Case information, which included demographics, clinical presentation, distribution by sub-regions, districts, ethnicity and sub-regions post-care outcomes, were retrospectively abstracted. Results: Central 671(34.15%), Southwestern 308(15.67%), Elgon 176(8.95%) and East central 163(8.29%) sub-regions had most patients. Mostly from administrative districts of Wakiso 167(8.50%), Mbarara 51(2.59%), Tororo 53(2.70%), Busia 33(1.68). Baganda, Banyakole, Bagisu and Basoga ethnic groups predominate. Patients from neighbouring countries were mainly from Rwanda 56(2.85%), South Sudan 24(1.22%), then Kenya 21(1.07%), and Rwandese, Dinka and Luo by ethnicity, respectively. Central and Southwestern sub-regions had the most post-care outcomes of the patients regarding living, death, and loss to follow-up. Conclusion: Patients are commonly from the administrative districts of Central, Southwestern, Elgon and East Central sub-regions and neighbouring countries of Rwanda, South Sudan and Kenya. Baganda, Banyakole, Bagisu and Basoga are the main ethnic groups. Central and Southwestern sub-regions are with most post-care outcomes.


Asunto(s)
Neoplasias Esofágicas , Etnicidad , Humanos , Neoplasias Esofágicas/etnología , Neoplasias Esofágicas/terapia , Uganda/epidemiología , Masculino , Femenino , Persona de Mediana Edad , Estudios Retrospectivos , Anciano , Etnicidad/estadística & datos numéricos , Adulto
2.
J Gastrointest Surg ; 28(7): 1126-1131, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38740256

RESUMEN

BACKGROUND: Hispanics are the fastest-growing minority and the second largest ethnic group in the United States, accounting for 18% of the national population. The American Cancer Society estimated 18,440 new cases of esophageal cancer (EC) in the United States in 2020. Hispanics are reported to be at high risk of EC. We sought to interrogate the demographic patterns of EC in Hispanics. Secondary objective was to examine evidence of socioeconomic disparities and differential therapy. METHODS: We identified Hispanic vs non-Hispanic patients with EC in the National Cancer Database between 2005 and 2015. Groups were statistically equated through propensity score-matched analysis. RESULTS: A total of 3205 Hispanics (3.8%) were identified among 85,004 patients with EC. We identified significant disparities between Hispanic and non-Hispanic groups. Disparities among Hispanics included higher prevalence of squamous EC, higher likelihood of stage IV cancer diagnosis, younger age, uninsured status, and income< $38,000. Hispanics were less likely to have surgical intervention or any type of treatment when compared to non-Hispanics. Multivariate analysis showed that age, ethnicity, treatment, histology, grade, stage, and Charlson-Deyo scores were independent predictors of survival. Treated Hispanics survived longer than non-Hispanics. CONCLUSION: Despite the lower prevalence of EC, there is a disproportionately higher prevalence of metastatic and untreated cases among Hispanics. This disparity may be explained by Hispanics' limited access to medical care, exacerbated by their socioeconomic and insurance status. Further study is warranted to examine these health disparities among Hispanics.


Asunto(s)
Bases de Datos Factuales , Neoplasias Esofágicas , Disparidades en Atención de Salud , Hispánicos o Latinos , Humanos , Hispánicos o Latinos/estadística & datos numéricos , Neoplasias Esofágicas/etnología , Neoplasias Esofágicas/epidemiología , Neoplasias Esofágicas/terapia , Neoplasias Esofágicas/patología , Masculino , Femenino , Persona de Mediana Edad , Estados Unidos/epidemiología , Anciano , Disparidades en Atención de Salud/estadística & datos numéricos , Disparidades en Atención de Salud/etnología , Estadificación de Neoplasias , Factores de Edad , Pacientes no Asegurados/estadística & datos numéricos , Factores Socioeconómicos , Carcinoma de Células Escamosas/etnología , Carcinoma de Células Escamosas/terapia , Carcinoma de Células Escamosas/epidemiología , Carcinoma de Células Escamosas/patología , Puntaje de Propensión , Renta/estadística & datos numéricos , Adulto , Adenocarcinoma/etnología , Adenocarcinoma/terapia , Adenocarcinoma/patología
3.
Am J Surg ; 232: 75-80, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38199873

RESUMEN

BACKGROUND: Despite Asian Americans having a heightened risk profile for esophageal cancer, racial disparities within this group have not been investigated. This study seeks to evaluate the 30-day postoperative outcomes for Asian Americans following esophagectomy. METHODS: A retrospective analysis was performed using ACS-NSQIP esophagectomy targeted database 2016-2021. A 1:3 propensity-score matching was applied to Asian Americans and Caucasians who underwent esophagectomy to compare their 30-day outcomes. RESULTS: There were 229 Asian Americans and 5303 Caucasians identified. Asian Americans were more likely to have squamous cell carcinoma than adenocarcinoma. After matching, 687 Caucasians were included. Asian Americans had higher pulmonary complications (22.27 â€‹% vs 16.01 â€‹%, p â€‹= â€‹0.04) especially pneumonia (16.59 â€‹% vs 11.06 â€‹%, p â€‹= â€‹0.04), renal dysfunction (2.62 â€‹% vs 0.44 â€‹%, p â€‹= â€‹0.01) especially progressive renal insufficiency (1.31 â€‹% vs 0.15 â€‹%, p â€‹< â€‹0.05), and bleeding events (18.34 â€‹% vs 9.02 â€‹%, p â€‹< â€‹0.01). In addition, Asian Americans had longer LOS (11.83 â€‹± â€‹9.39 vs 10.23 â€‹± â€‹7.34 days, p â€‹= â€‹0.03). CONCLUSION: Asian Americans were found to face higher 30-day surgical complications following esophagectomy. Continued investigation into the underlying causes and potential mitigation strategies for these disparities are needed.


Asunto(s)
Asiático , Neoplasias Esofágicas , Esofagectomía , Complicaciones Posoperatorias , Puntaje de Propensión , Humanos , Esofagectomía/efectos adversos , Masculino , Femenino , Complicaciones Posoperatorias/etnología , Complicaciones Posoperatorias/epidemiología , Persona de Mediana Edad , Estudios Retrospectivos , Asiático/estadística & datos numéricos , Neoplasias Esofágicas/cirugía , Neoplasias Esofágicas/etnología , Anciano , Bases de Datos Factuales , Estados Unidos/epidemiología , Población Blanca/estadística & datos numéricos , Adenocarcinoma/cirugía , Adenocarcinoma/etnología
4.
Cancer Epidemiol Biomarkers Prev ; 33(2): 254-260, 2024 02 06.
Artículo en Inglés | MEDLINE | ID: mdl-38015776

RESUMEN

BACKGROUND: It is unclear whether health-related quality of life (HRQOL) disparities exist between racial/ethnic groups in older patients with esophageal cancer, pre- and post-diagnosis. METHODS: Using the SEER-MHOS (Surveillance, Epidemiology, and End Results and Medicare Health Outcomes Survey) national database, we included patients ages 65-years-old or greater with esophageal cancer diagnosed from 1996 to 2017. HRQOL data within 36 months before and after diagnosis were measured by the Physical Component Summary (PCS) and Mental Component Summary (MCS) scores from the SF-36 and VR-12 instruments. Total combined score (TCS) was reflected by both PCS and MCS. RESULTS: We identified 1,312 patients, with evaluable data on 873 patients pre-diagnosis and 439 post-diagnosis. On pre-diagnosis cohort MVA, the MCS was better for White over Hispanic patients (54.1 vs. 48.6, P = 0.012). On post-diagnosis cohort MVA, PCS was better for Hispanic compared with White (39.8 vs. 34.5, P = 0.036) patients, MCS was better for Asian compared with White (48.9 vs. 40.9, P = 0.034) patients, and TCS better for Asian compared with White (92.6 vs. 76.7, P = 0.003) patients. CONCLUSIONS: In older patients with esophageal cancer, White patients had better mental HRQOL as compared with Hispanic patients pre-diagnosis. However, post-diagnosis, White patients had worse mental and physical HRQOL compared with Asian and Hispanic patients, respectively, suggesting a greater negative impact on self-reported HRQOL in White patients with esophageal cancer. IMPACT: To our knowledge, this study is the first to explore HRQOL differences in patients with esophageal cancer of various racial and ethnic groups and warrants further validation in future studies.


Asunto(s)
Neoplasias Esofágicas , Inequidades en Salud , Calidad de Vida , Anciano , Humanos , Neoplasias Esofágicas/epidemiología , Neoplasias Esofágicas/etnología , Etnicidad , Hispánicos o Latinos , Medicare , Estados Unidos/epidemiología , Blanco , Asiático , Programa de VERF/estadística & datos numéricos
5.
Isr Med Assoc J ; 24(2): 112-116, 2022 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-35187901

RESUMEN

BACKGROUND: There has been a general reduction over the last 20 years in the incidence within Israel of gastric cancer (GC). This has particularly been noted in the Jewish population with a slight increase in the incidence of cancer of the gastroesophageal junction among Jews of Sephardi origin. Given the diversity of individual ethnic subpopulations, the effects of GC incidence in second-generation immigrant Jews, particularly from high prevalence regions (e.g., the former Soviet Union, Iraq, and Iran), awaits determination. There are currently no national data on GC-specific mortality. The most recent available cross-correlated Israeli National Cancer Registry (INCR) and International Association for Cancer Research (IARC) incidence data for GC of the body and antrum in Israel are presented. Some of the challenges associated with GC monitoring in the changing Israeli population are discussed. We propose the establishment of a national GC management committee designed to collect demographic and oncological data in operable cases with the aim of recording and improving GC-specific outcomes. We believe that there is value in the development of a national surgical planning program, which oversees training and accreditation in a dynamic environment that favors the wider use of neoadjuvant therapies, minimally invasive surgery and routine extended (D2) lymphadenectomy. These changes should be supported by assessable enhanced recovery programs.


Asunto(s)
Neoplasias Esofágicas/epidemiología , Unión Esofagogástrica/patología , Neoplasias Gástricas/epidemiología , Acreditación/organización & administración , Emigrantes e Inmigrantes/estadística & datos numéricos , Neoplasias Esofágicas/etnología , Neoplasias Esofágicas/cirugía , Unión Esofagogástrica/cirugía , Etnicidad , Humanos , Incidencia , Israel/epidemiología , Judíos , Neoplasias Gástricas/etnología , Neoplasias Gástricas/cirugía
6.
BMC Cancer ; 21(1): 1057, 2021 Sep 26.
Artículo en Inglés | MEDLINE | ID: mdl-34563149

RESUMEN

BACKGROUND: Brain metastases were rare in esophageal cancer patients. Using the Surveillance, Epidemiology, and End Results (SEER) database, the present study investigated the incidence, risk and prognostic factors of brain metastases in esophageal cancer patients. METHODS: Retrieving esophageal cancer patients diagnosed between 2010 and 2018 from the SEER database, univariable and multivariable logistic and cox regression models were used to investigate the risk factors for brain metastases development and prognosis, respectively. The brain metastases predicting nomogram was constructed, evaluated and validated. The overall survival (OS) of patients with brain metastases was analyzed by Kaplan-Meier method. RESULTS: A total of 34,107 eligible esophageal cancer patients were included and 618 of them were diagnosed with brain metastases (1.8%). The median survival of the brain metastatic esophageal cancer patients was 5 (95% CI: 5-7) months. The presence of bone metastases and lung metastases were the homogeneously associated factors for the development and prognosis of brain metastases in esophageal cancer patients. Patients younger than 65 years, American Indian/Alaska Native race (vs. White), overlapping lesion (vs. Upper third), esophageal adenocarcinoma histology subtype, higher N stage, and liver metastases were positively associated with brain metastases occurrence. The calibration curve, ROC curve, and C-index exhibited good performance of the nomogram for predicting brain metastases. CONCLUSIONS: Homogeneous and heterogeneous factors were found for the development and prognosis of brain metastases in esophageal cancer patients. The nomogram had good calibration and discrimination for predicting brain metastases.


Asunto(s)
Neoplasias Encefálicas/secundario , Neoplasias Esofágicas/patología , Nomogramas , Programa de VERF , Adenocarcinoma/secundario , Anciano , Neoplasias Óseas/epidemiología , Neoplasias Óseas/secundario , Neoplasias Encefálicas/epidemiología , Neoplasias Encefálicas/etnología , Neoplasias Encefálicas/mortalidad , Intervalos de Confianza , Neoplasias Esofágicas/epidemiología , Neoplasias Esofágicas/etnología , Neoplasias Esofágicas/mortalidad , Femenino , Humanos , Incidencia , Estimación de Kaplan-Meier , Neoplasias Hepáticas/epidemiología , Neoplasias Hepáticas/secundario , Modelos Logísticos , Neoplasias Pulmonares/epidemiología , Neoplasias Pulmonares/secundario , Masculino , Persona de Mediana Edad , Pronóstico , Factores de Riesgo
7.
Medicine (Baltimore) ; 100(28): e26597, 2021 Jul 16.
Artículo en Inglés | MEDLINE | ID: mdl-34260541

RESUMEN

BACKGROUND: Esophageal cancer is the eighth most frequent and sixth most fatal cancer worldwide. This study aimed to investigate the clinical characteristics and prognostic significance of yes related protein 1 (YAP1) and transcriptional co-activator with PDZ binding motif (TAZ) in patients with esophageal squamous cell carcinoma (ESCC). METHODS: A total of 306 ESCC pathological specimens and adjacent tissues (as control; tissues from the esophageal mucosa >5 cm from the edge of the tumor) were collected between January, 2008 and December, 2018. Immunohistochemical staining was used to assess the expression of YAP1 and TAZ proteins in the ESCC and adjacent tissues, and their relationship with clinicopathological parameters was evaluated using SPSS 21.0 software. RESULTS: YAP1 and TAZ proteins were highly expressed in ESCC, and their expression was closely related to TNM stage and lymph node metastasis. Expression of YAP1 was associated with tumor size (P = .029), differentiation (P = .000), depth of invasion (P = .001), and TNM stage (P = .000). Expression of TAZ was associated with tumor size (P = .034), differentiation (P = .000), depth of invasion (P = .029), lymph node metastasis (P = .006), and ethnicity (P < .001). The expression of YAP1 protein was positively correlated with the expression of TAZ protein (r = 0.257, P < .05). YAP1 and TAZ expression (P = .039 and .000, respectively), tumor size (P = .041), and lymph node metastasis (P = .001) significantly affected the overall survival of patients with ESCC, and represent independent factors for overall survival. CONCLUSION: YAP1 and TAZ proteins are highly expressed in ESCC, and closely related to the clinical and pathological parameters such as the diameter of the tumor, degree of differentiation, and depth of invasion, indicating that YAP1 and TAZ may be involved in the development of ESCC. YAP1 and TAZ may be used as prognostic markers in ESCC.


Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/biosíntesis , Neoplasias Esofágicas/genética , Carcinoma de Células Escamosas de Esófago/genética , Péptidos y Proteínas de Señalización Intracelular/biosíntesis , Factores de Transcripción/biosíntesis , Anciano , Biomarcadores de Tumor , Neoplasias Esofágicas/etnología , Neoplasias Esofágicas/patología , Carcinoma de Células Escamosas de Esófago/etnología , Carcinoma de Células Escamosas de Esófago/patología , Etnicidad , Femenino , Humanos , Estimación de Kaplan-Meier , Metástasis Linfática , Masculino , Persona de Mediana Edad , Invasividad Neoplásica , Estadificación de Neoplasias , Pronóstico , Análisis de Supervivencia , Proteínas Coactivadoras Transcripcionales con Motivo de Unión a PDZ , Carga Tumoral , Proteínas Señalizadoras YAP
8.
J Surg Oncol ; 124(4): 521-528, 2021 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34061359

RESUMEN

BACKGROUND: Racial disparities currently exist for the utilization rate of esophagectomy for Black patients with operable esophageal carcinoma. METHODS: A total of 37 271 cases with the American Joint Committee on Cancer clinical stage I, II, and III esophageal carcinoma that were reported to the National Cancer Database were analyzed between 2004 and 2016. A multivariable-adjusted logistic regression model was used to evaluate differences in the odds ratio of esophagectomy not being recommended based on race. Kaplan-Meier curves and log-rank tests were used to evaluate differences in overall survival. Propensity score methodology with inverse probability of treatment weighting (IPTW) was used to balance baseline differences in patient demographics. RESULTS: After IPTW adjustment, we identified 30 552 White patients and 3529 Black patients with clinical stage I-III esophageal carcinoma. Black patients had three times greater odds of not being recommended for esophagectomy (odds ratio: 3.03, 95% confidence interval: 2.67-3.43, p < 0.0001) compared to White patients. Black patients demonstrated significantly worse 3- and 5-year overall survival rates compared to White patients (log-rank p < 0.0001). CONCLUSION: Black patients with clinical stage I-III esophageal cancer were significantly less likely to be recommended for esophagectomy even after adjusting for baseline demographic covariates compared to White patients.


Asunto(s)
Negro o Afroamericano/estadística & datos numéricos , Neoplasias Esofágicas/cirugía , Esofagectomía/estadística & datos numéricos , Personal de Salud/psicología , Disparidades en Atención de Salud , Pautas de la Práctica en Medicina/estadística & datos numéricos , Población Blanca/estadística & datos numéricos , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias Esofágicas/etnología , Neoplasias Esofágicas/patología , Esofagectomía/tendencias , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Retrospectivos , Tasa de Supervivencia , Adulto Joven
9.
Clin Transl Oncol ; 23(11): 2382-2393, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-34075547

RESUMEN

OBJECTIVES: High-risk human papillomavirus (HR-HPV) is an important risk factor for esophageal cancer. Macrophages constitute a crucial immune medium for regulating HPV-related tumors; however, the specific regulatory mechanisms remain unknown. Therefore, the purpose of our current study was to investigate the mechanism by which HPV16E6 regulates macrophages to promote the invasion and metastasis of esophageal cancer. METHODS: HPV16E6 infection was detected by polymerase chain reaction. Immunohistochemistry was used to verify the distribution of tumor-associated macrophages (TAMs) and MMP-9 expression in esophageal squamous cell carcinoma tissues (ESCCs), and cancer adjacent normal tissues (CANs) from Kazakh patients. ESCC cells were transfected with a plasmid over-expressing HPV16E6 and non-contact cocultured with macrophages. RESULTS: The infection rate of HPV16E6 in Kazakh ESCCs was clearly higher than that in CANs (P < 0.05). The density of CD163-positive TAMs was significantly positively correlated with HPV16E6 infection in ESCCs (P < 0.05). After coculturing macrophages and EC9706 cells transfected with the HPV16E6 plasmid, the phenotype of macrophages transformed into M2 macrophages. The migration and invasion ability of ESCC cells were higher in the HPV16E6-transfected and coculture group than in the HPV16E6 empty vector-transfected and non-cocultured HPV16E6-transfected groups (all P < 0.05). The density of M2-like TAMs in ESCCs was positively correlated with the level of MMP-9 expression. MMP-9 expression in the HPV16E6-ESCC coculture macrophages group was substantially higher than that in controls (all P < 0.05). CONCLUSIONS: HPV16 infection mediates tumor-associated macrophages to promote ESCC invasion and migration.


Asunto(s)
Neoplasias Esofágicas/patología , Carcinoma de Células Escamosas de Esófago/patología , Papillomavirus Humano 16 , Proteínas Oncogénicas Virales/metabolismo , Infecciones por Papillomavirus/complicaciones , Proteínas Represoras/metabolismo , Macrófagos Asociados a Tumores/patología , Antígenos CD/metabolismo , Antígenos de Diferenciación Mielomonocítica/metabolismo , Diferenciación Celular , China/etnología , Técnicas de Cocultivo , Neoplasias Esofágicas/etnología , Neoplasias Esofágicas/virología , Carcinoma de Células Escamosas de Esófago/etnología , Carcinoma de Células Escamosas de Esófago/virología , Humanos , Metaloproteinasa 9 de la Matriz/metabolismo , Invasividad Neoplásica , Proteínas Oncogénicas Virales/genética , Infecciones por Papillomavirus/etnología , Fenotipo , Receptores de Superficie Celular/metabolismo , Proteínas Represoras/genética , Microambiente Tumoral , Macrófagos Asociados a Tumores/metabolismo , Macrófagos Asociados a Tumores/virología
10.
Clin. transl. oncol. (Print) ; 23(2): 275-282, feb. 2021.
Artículo en Inglés | IBECS | ID: ibc-220611

RESUMEN

Objective Recently, numerous studies have yielded inconsistent results regarding the effect of metformin on esophageal cancer risk in type 2 diabetes mellitus patients. The purpose of this study is to systematically assess this effect using meta-analysis. Methods We searched clinical studies on metformin and esophageal cancer risk in PubMed, Embase, and the Cochrane Library. After literature screening, a series of meta-analyses were conducted using RevMan 5.3 software. The pooled hazard ratio (HR) and the corresponding 95% confidence interval (CI) were used as the effect size. Results Five eligible studies (four cohort studies and one case–control study) were included for our meta-analysis using a random-effect model. The analysis showed that metformin could not reduce esophageal cancer risk in type 2 diabetes mellitus patients (HR 0.88, 95% CI 0.60–1.28, P > 0.05). Subgroup analyses by geographic location showed that metformin significantly reduced esophageal cancer risk in Asian patients with type 2 diabetes mellitus (HR 0.59, 95% CI 0.39–0.91, P = 0.02), without heterogeneity between studies (P = 0.80 and I2 = 0%). Conclusions Overall, our systematic review and meta-analysis demonstrate that metformin does not reduce esophageal cancer risk in type 2 diabetes mellitus patients. However, a significant reduction in esophageal cancer risk in Asian populations remains to be clarified (AU)


Asunto(s)
Humanos , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/etnología , Neoplasias Esofágicas/etnología , Neoplasias Esofágicas/prevención & control , Hipoglucemiantes , Metformina/administración & dosificación , Estudios Retrospectivos , Estudios de Casos y Controles , Intervalos de Confianza , Estudios Prospectivos
11.
Biomarkers ; 26(2): 103-113, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-33434077

RESUMEN

Purpose: Gastrointestinal cancers (GICs) account for about a quarter of cancers. Lately, the circulating microRNAs as a non-invasive biomarker for identifying and monitoring diseases have been recognized. Several studies have examined the role of miR-21 in digestive system carcinoma. We conducted a meta-analysis to assess the diagnostic role of miR-21 in GICs.Methods: Seventeen studies involving 1700 individuals were included in this meta-analysis. The pooled sensitivity, specificity, PLR, NLR, DOR, AUC, SROC, and Q* index were calculated based on true-positive, true-negative, false-negative, and false-positive. Moreover, the subgroup analyses have been performed for miR-21 based on sample types (serum/plasma), normalized genes (U6, miR-16, and miR-39), and ethnicity.Results: The pooled sensitivity 0.722 (95% CI: 0.70-0.74), specificity 0.820 (95% CI: 0.801-0.838), PLR 4.375 (95% CI: 3.226-5.933), NLR 0.308 (95% CI: 0.239-0.398), DOR 16.06 (95% CI: 9.732-26.53) as well as AUC 0.86, and Q* index 0.79 represented the high-grade diagnostic precision of miR-21 in identifying GICs (ESCC, GC, CRC, HCC, and PC).Conclusion: This meta-analysis demonstrated that circulating miR-21 levels can be used to monitor the digestive system carcinomas. Therefore, miR-21 can be a useful biomarker of progression and fair diagnosis in GICs patients.


Asunto(s)
Carcinoma Hepatocelular/diagnóstico , Neoplasias Esofágicas/diagnóstico , Neoplasias Gastrointestinales/diagnóstico , Neoplasias Hepáticas/diagnóstico , MicroARNs/genética , Neoplasias Pancreáticas/diagnóstico , Neoplasias Gástricas/diagnóstico , Pueblo Asiatico , Biomarcadores de Tumor/sangre , Biomarcadores de Tumor/genética , Carcinoma Hepatocelular/sangre , Carcinoma Hepatocelular/etnología , Carcinoma Hepatocelular/genética , Estudios de Casos y Controles , Neoplasias Esofágicas/sangre , Neoplasias Esofágicas/etnología , Neoplasias Esofágicas/genética , Neoplasias Gastrointestinales/sangre , Neoplasias Gastrointestinales/etnología , Neoplasias Gastrointestinales/genética , Regulación Neoplásica de la Expresión Génica , Humanos , Neoplasias Hepáticas/sangre , Neoplasias Hepáticas/etnología , Neoplasias Hepáticas/genética , MicroARNs/sangre , Neoplasias Pancreáticas/sangre , Neoplasias Pancreáticas/etnología , Neoplasias Pancreáticas/genética , Sensibilidad y Especificidad , Neoplasias Gástricas/sangre , Neoplasias Gástricas/etnología , Neoplasias Gástricas/genética , Población Blanca
12.
Clin Transl Oncol ; 23(2): 275-282, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-32507907

RESUMEN

OBJECTIVE: Recently, numerous studies have yielded inconsistent results regarding the effect of metformin on esophageal cancer risk in type 2 diabetes mellitus patients. The purpose of this study is to systematically assess this effect using meta-analysis. METHODS: We searched clinical studies on metformin and esophageal cancer risk in PubMed, Embase, and the Cochrane Library. After literature screening, a series of meta-analyses were conducted using RevMan 5.3 software. The pooled hazard ratio (HR) and the corresponding 95% confidence interval (CI) were used as the effect size. RESULTS: Five eligible studies (four cohort studies and one case-control study) were included for our meta-analysis using a random-effect model. The analysis showed that metformin could not reduce esophageal cancer risk in type 2 diabetes mellitus patients (HR 0.88, 95% CI 0.60-1.28, P > 0.05). Subgroup analyses by geographic location showed that metformin significantly reduced esophageal cancer risk in Asian patients with type 2 diabetes mellitus (HR 0.59, 95% CI 0.39-0.91, P = 0.02), without heterogeneity between studies (P = 0.80 and I2 = 0%). CONCLUSIONS: Overall, our systematic review and meta-analysis demonstrate that metformin does not reduce esophageal cancer risk in type 2 diabetes mellitus patients. However, a significant reduction in esophageal cancer risk in Asian populations remains to be clarified.


Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Neoplasias Esofágicas/prevención & control , Hipoglucemiantes/farmacología , Metformina/farmacología , Pueblo Asiatico , Estudios de Casos y Controles , Intervalos de Confianza , Diabetes Mellitus Tipo 2/etnología , Neoplasias Esofágicas/etnología , Humanos , Modelos de Riesgos Proporcionales , Estudios Prospectivos , Sesgo de Publicación , Estudios Retrospectivos , Riesgo
13.
Genet Test Mol Biomarkers ; 24(12): 804-811, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-33290139

RESUMEN

Background: Upper gastrointestinal tract cancers are the leading causes of cancer-related deaths in Northwest China and they share many similarities in terms of histological type, risk factors, and genetic variants. We hypothesized that shared common single-nucleotide polymorphisms (SNPs) in the p53 pathway exist between patients with gastric and esophageal cancer (EC) patients. Materials and Methods: A case-control study to examine genetic variants in the p53 pathway was conducted with subjects from a high-incidence area for upper gastrointestinal cancers of China. Multiple logistic regression analyses were used to estimate the association of genotypes with gastric cancer and EC risks. Median survival was estimated by using the Kaplan-Meier method and compared by using the log-rank test. Results: Compared with the rs1042522 Pro allele, the rs1042522 Arg allele was associated with an increased risk of gastric cancer (1.810×) and an increased risk of EC (2.285×). The rs1042522 Arg allele carriers who also smoked or consumed alcohol had a further increased risk for gastric cancer odds ratios (ORsmoking = 2.422, ORdrinking = 5.152) and EC (ORsmoking = 5.310, ORdrinking = 8.359). No association was found between the rs1042522 genotypes and survival (p > 0.05). Conclusion: The p53 rs1042522 arg allele together with tobacco smoking and alcohol drinking, was associated with an increased risk, for gastric cancer and EC, but not the survival among northwestern Chinese patients. These associations warrant confirmatory studies.


Asunto(s)
Adenocarcinoma/genética , Pueblo Asiatico/genética , Carcinoma de Células Escamosas/genética , Neoplasias Esofágicas/genética , Genes p53 , Neoplasias Gástricas/genética , Adenocarcinoma/etnología , Consumo de Bebidas Alcohólicas/epidemiología , Alelos , Carcinoma de Células Escamosas/etnología , Estudios de Casos y Controles , China/epidemiología , Inhibidor p21 de las Quinasas Dependientes de la Ciclina/genética , ADN de Neoplasias/genética , Neoplasias Esofágicas/etnología , Femenino , Predisposición Genética a la Enfermedad , Genotipo , Humanos , Estimación de Kaplan-Meier , Masculino , Polimorfismo de Nucleótido Simple , Fumar/epidemiología , Neoplasias Gástricas/etnología
14.
Biosci Rep ; 40(8)2020 08 28.
Artículo en Inglés | MEDLINE | ID: mdl-32744314

RESUMEN

It is believed that an individual's hereditary factors may be involved in the development of esophageal cancer (EC). The present study recruited 721 esophageal squamous cell carcinoma (ESCC) cases and 1208 controls and explored the roles of single nucleotide polymorphisms (SNPs) in the interleukin-4 (IL-4), IL-10, and herpesvirus entry mediator (HVEM) genes in contributing to ESCC risk. IL-4, IL-10, and HVEM SNPs were analyzed by employing an SNPscan method. After adjustment for body mass index (BMI), smoking, drinking, age and gender, we identified that the rs2070874 T>C locus in IL-4 gene decreased the risk of ESCC (CC vs. TT: P=0.008; CC vs. TT/TC: P=0.010). After a stratified analysis, we suggested that the IL-4 rs2070874 T>C variants might be a protective factor for ESCC in male, ≥63 years old, never smoking, drinking and BMI < 24 kg/m2 subgroups. In addition, we identified that the rs2243263 G>C polymorphism in IL-4 gene was a risk factor for ESCC development in the BMI ≥ 24 kg/m2 subgroup (GC vs. GG: P=0.030 and GC/CC vs. GG: P=0.018). We identified an association of the IL-4 rs2070874 T>C SNP with the decreased susceptibility of ESCC in stage I/II subgroup. Finally, we found an association of the IL-10 rs1800872 T>G SNP with a worse differentiation (TG vs. TT: P=0.048 and GG/TG vs. TT: P=0.032). In conclusion, the findings indicate a potential importance of IL-4 rs2070874 T>C, IL-4 rs2243263 G>C and IL-10 rs1800872 T>G SNPs in the development of ESCC.


Asunto(s)
Biomarcadores de Tumor/genética , Neoplasias Esofágicas/genética , Carcinoma de Células Escamosas de Esófago/genética , Interleucina-10/genética , Interleucina-4/genética , Polimorfismo de Nucleótido Simple , Anciano , Pueblo Asiatico/genética , Estudios de Casos y Controles , China/epidemiología , Neoplasias Esofágicas/etnología , Neoplasias Esofágicas/patología , Carcinoma de Células Escamosas de Esófago/etnología , Carcinoma de Células Escamosas de Esófago/patología , Femenino , Estudios de Asociación Genética , Predisposición Genética a la Enfermedad , Humanos , Masculino , Persona de Mediana Edad , Obesidad/etnología , Fenotipo , Miembro 14 de Receptores del Factor de Necrosis Tumoral/genética , Medición de Riesgo , Factores de Riesgo
15.
Gastric Cancer ; 23(5): 765-779, 2020 09.
Artículo en Inglés | MEDLINE | ID: mdl-32488651

RESUMEN

BACKGROUND: The literature on the prognostic relevance of signet-ring cell (SRC) histology in gastric cancer (GC) is controversial which is most likely related to inconsistent SRC classification based on haematoxylin-eosin staining. We hypothesised that mucin stains can consistently identify SRC-GC and predict GC patient outcome. METHODS: We performed a comprehensive literature review on mucin stains in SRC-GC and characterised the mucin expression in 851 Caucasian GC and 410 Asian GC using Alcian Blue (AB)-Periodic Acid-Schiff (PAS), MUC2 (intestinal-type mucin), and MUC5AC (gastric-type mucin). The relationship between mucin expression and histological phenotype [poorly cohesive (PC) including proportion of SRCs, non-poorly cohesive (non-PC), or mucinous (MC)], clinicopathological variables, and patient outcome was analysed. RESULTS: Depending on mucin expression and cut-offs, the positivity rates of SRC-GC reported in the literature varied from 6 to 100%. Patients with MUC2 positive SRC-GC or SRC-GC with (gastro)intestinal phenotype had poorest outcome. In our cohort study, PC with ≥ 10% SRCs expressed more frequently MUC2, MUC5AC, and ABPAS (p < 0.001, p = 0.004 and p < 0.001, respectively). Caucasians with AB positive GC or combined ABPAS-MUC2 positive and MUC5AC negative had poorest outcome (all p = 0.002). This association was not seen in Asian patients. CONCLUSIONS: This is the first study to suggest that mucin stains do not help to differentiate between SRC-GC and non-SRC-GC. However, mucin stains appear to be able to identify GC patients with different outcome. To our surprise, the relationship between outcome and mucin expression seems to differ between Caucasian and Asian GC patients which warrants further investigations.


Asunto(s)
Pueblo Asiatico/estadística & datos numéricos , Carcinoma de Células en Anillo de Sello/patología , Neoplasias Esofágicas/patología , Mucina-1/metabolismo , Neoplasias Gástricas/patología , Población Blanca/estadística & datos numéricos , Anciano , Carcinoma de Células en Anillo de Sello/etnología , Carcinoma de Células en Anillo de Sello/metabolismo , Carcinoma de Células en Anillo de Sello/terapia , Estudios de Cohortes , Terapia Combinada , Neoplasias Esofágicas/etnología , Neoplasias Esofágicas/metabolismo , Neoplasias Esofágicas/terapia , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Neoplasias Gástricas/etnología , Neoplasias Gástricas/metabolismo , Neoplasias Gástricas/terapia , Tasa de Supervivencia
16.
Cancer Med ; 9(15): 5678-5686, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32573964

RESUMEN

BACKGROUND: Racial/ethnic differences in mortality have not been well studied for either non-cardia gastric cancer (NCGC) or cardia gastric cancer (CGC). The aim of this study was to examine the US mortality rates for these cancer subtypes, as well as esophageal adenocarcinoma (EAC) as a comparator. METHODS: We identified 14 164 individuals who died from NCGC, 5235 from CGC, and 13 982 from EAC in the Surveillance, Epidemiology, and End Results database between 2004 and 2016. Age-adjusted incidence-based mortality rates and corresponding annual percent changes (APCs) were calculated. Analyses were stratified by race/ethnicity, age, and stage of disease at diagnosis. RESULTS: The mortality rate in NCGC was two- to threefold higher in blacks, Hispanics, and Asians/Pacific Islanders (PI) than non-Hispanic whites, and was significant across all age groups and stages of disease (P < .01). Mortality in CGC was higher in non-Hispanic whites than blacks and Asians/PI, particularly in individuals in the 50-64 year age group and those with stage IV disease. Mortality in EAC was two- to sixfold higher in non-Hispanic whites than all other groups across all age groups and stages of disease. From 2004 to 2016, mortality rates were stable across all racial/ethnic groups in NCGC and CGC, and in minority groups with EAC, but have been rising in non-Hispanic whites with EAC (APC 3.03, 95% CI 0.17-5.96). CONCLUSIONS: This is the largest study of incidence-based mortality in CGC and NCGC and demonstrates racial/ethnic differences in mortality between these subtypes. Mortality rates for NCGC are highest in minority groups, and have been stable in recent years despite declining incidence. Mortality rates for CGC are marginally higher in middle-aged non-Hispanic whites with advanced disease, though have remained stable. In contrast, mortality in EAC has been rising for non-Hispanic whites, in parallel to incidence. Further studies are needed to refine prevention strategies for high-risk individuals dying from these specific cancer subtypes.


Asunto(s)
Adenocarcinoma/etnología , Neoplasias Esofágicas/etnología , Neoplasias Gástricas/etnología , Adenocarcinoma/mortalidad , Adulto , Anciano , Neoplasias Esofágicas/mortalidad , Etnicidad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias Gástricas/mortalidad , Adulto Joven
17.
Dis Esophagus ; 33(2)2020 Mar 05.
Artículo en Inglés | MEDLINE | ID: mdl-31076759

RESUMEN

The incidence of esophageal cancer has increased steadily in the last decades in the United States. The aim of this paper was to characterize disparities in esophageal cancer treatment in different racial and socioeconomic population groups and compare long-term survival among different treatment modalities. A retrospective analysis of the National Cancer Database was performed including adult patients (≥18 years old) with a diagnosis of resectable (stages I-III) esophageal cancer between 2004 and 2015. Multivariable logistic regression models were used to determine the odds of being offered no treatment at all and surgical treatment across race, primary insurance, travel distance, income, and education levels. Multivariable Cox proportional hazards models were used to compare 5-year survival rates across different treatment modalities. A total of 60,621 esophageal cancer patients were included. Black patients, uninsured patients, and patients living in areas with lower levels of education were more likely to be offered no treatment. Similarly, black race, female patients, nonprivately insured patients, and those living in areas with lower median residential income and lower education levels were associated with lower rates of surgery. Patients receiving surgical treatment, compared to both no treatment and definitive chemoradiation, had significant better long-term survival in stage I, II, and III esophageal cancer. In conclusion, underserved patients with esophageal cancer appear to have limited access to surgical care, and are, in fact, more likely to not be offered any treatment at all. Considering the survival benefits associated with surgical resection, greater public health efforts to reduce disparities in esophageal cancer are needed.


Asunto(s)
Neoplasias Esofágicas , Etnicidad , Disparidades en el Estado de Salud , Disparidades en Atención de Salud/estadística & datos numéricos , Determinantes Sociales de la Salud , Factores Socioeconómicos , Poblaciones Vulnerables , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Quimioradioterapia , Bases de Datos Factuales , Neoplasias Esofágicas/economía , Neoplasias Esofágicas/etnología , Neoplasias Esofágicas/mortalidad , Neoplasias Esofágicas/terapia , Esofagectomía , Femenino , Accesibilidad a los Servicios de Salud/economía , Disparidades en Atención de Salud/economía , Disparidades en Atención de Salud/etnología , Humanos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Modelos de Riesgos Proporcionales , Estudios Retrospectivos , Tasa de Supervivencia , Estados Unidos/epidemiología , Adulto Joven
18.
Crit Care Nurs Q ; 43(1): 86-98, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-31789882

RESUMEN

Esophageal cancer (EC) is a prevalent type of cancer, affecting more than 16 000 people annually in the United States. Being a high-burden disease, the comprehensive management of EC is challenging, particularly for older adults. In addition, Asian countries have some of the highest age-standardized incidence rates of EC in the world. Epidemiologic studies have revealed that cigarette and cigar smoking, alcohol drinking, obesity, being overweight, and areca chewing increase the risk of EC. This integrative review aims to elucidate the association between lifestyle factors such dietary habits, smoking, and alcohol consumption and EC among the Asian populations with Chinese, Japanese, and Taiwanese ethnicity. The synthesis of the literature found that environmental factors play an important role in the risk of EC occurrence. Although most of the risk factors showed a positive relationship in increasing the risk, studies included in this review reported inconclusive results on whether tea and coffee are risk factors. The consumption of very hot beverages and low intake of green vegetable are associated with EC. Smoking, alcohol intake, and their interaction with diets were found to be the biggest factor in the development of EC. Registered nurses can educate about esophageal thermal injury among persons who have preference for drinking burning-hot beverages and those with multiple risk factors, such as those who smoke and drink excess alcohol, as well as promoting health behaviors and serving as patient advocates.


Asunto(s)
Pueblo Asiatico , Dieta , Neoplasias Esofágicas/etnología , Neoplasias Esofágicas/epidemiología , Estilo de Vida , Consumo de Bebidas Alcohólicas , Humanos , Obesidad , Factores de Riesgo , Fumar , Estados Unidos
19.
Semin Thorac Cardiovasc Surg ; 32(2): 347-354, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-31866573

RESUMEN

Social determinants of health have been associated with poor outcomes in esophageal cancer. Primary language and immigration status have not been examined in relation to esophageal cancer outcomes. This study aims to investigate the impact of these variables on stage of presentation, treatment, and outcomes of esophageal cancer patients at an urban safety-net hospital. Clinical data of patients with esophageal cancer at our institution between 2003 and 2018 were reviewed. Demographic, tumor, and treatment characteristics were obtained. Outcomes included median overall survival, stage-specific survival, and utilization of surgical and perioperative therapy. Statistical analysis was conducted using Chi-square test, Fisher's exact tests, Kaplan-Meier method, and logistic regression. There were 266 patients; 77% were male. Mean age was 63.9 years, 23.7% were immigrants, 33.5% were uninsured/Medicaid, and 16.2% were non-English speaking. Adenocarcinoma was diagnosed in 55.3% and squamous cell in 41.0%. More patients of non-Hispanic received esophagectomies when compared to those of Hispanic origin (64% vs 25%, P = 0.012). Immigrants were less likely to undergo esophagectomy compared to US-born patients (42% vs 76%, P = 0.001). Patients with adenocarcinoma were more likely than squamous cell carcinoma patients to undergo esophagectomy (odds ratio = 4.40, 95% confidence interval 1.61-12.01, P = 0.004). More commercially/privately insured patients (75%) received perioperative therapy compared to Medicaid/uninsured (54%) and Medicare (49%) patients (P = 0.030). There was no association between demographic factors and the utilization of perioperative chemoradiation for patients with operable disease. Approximately 23% of patients with operable disease were too frail or declined to undergo surgical intervention. In this small single-center study, race and primary language were not associated with median survival for patients treated for esophageal cancer. US-born patients experienced higher surgical utilization and privately insured patients were more likely to receive perioperative therapy. Many patients with operable cancer were too frail to undergo a curative surgery. Studies should expand on the relationships between social determinants of health and nonclinical services on delivery of care and survival of vulnerable populations with esophageal cancer.


Asunto(s)
Adenocarcinoma/cirugía , Emigrantes e Inmigrantes , Neoplasias Esofágicas/cirugía , Carcinoma de Células Escamosas de Esófago/cirugía , Esofagectomía , Disparidades en Atención de Salud/etnología , Proveedores de Redes de Seguridad , Determinantes Sociales de la Salud/etnología , Poblaciones Vulnerables , Adenocarcinoma/etnología , Adenocarcinoma/mortalidad , Anciano , Boston/epidemiología , Quimioradioterapia Adyuvante , Neoplasias Esofágicas/etnología , Neoplasias Esofágicas/mortalidad , Carcinoma de Células Escamosas de Esófago/etnología , Carcinoma de Células Escamosas de Esófago/mortalidad , Esofagectomía/efectos adversos , Esofagectomía/mortalidad , Femenino , Estado de Salud , Humanos , Seguro de Salud , Masculino , Persona de Mediana Edad , Terapia Neoadyuvante , Factores Raciales , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Factores de Tiempo , Resultado del Tratamiento
20.
Zhonghua Yu Fang Yi Xue Za Zhi ; 53(11): 1084-1087, 2019 Nov 06.
Artículo en Chino | MEDLINE | ID: mdl-31683391

RESUMEN

The screening, early diagnosis and early treatment project of the upper gastrointestinal cancer had achieved good results since its launch. However, from a national perspective, the endoscopic screening of upper gastrointestinal cancer was still not optimistic, such as the poor rate of the early diagnosis, the low rate of 5-year survival in rural areas, and the disparity of the standardized screening and diagnosis in different areas. Therefore, the situation of upper gastrointestinal cancer prevention and treatment is still severe. Under the guidance of the "Healthy China 2030" plan, based on the international experience and domestic actual circumstance, it is suggested that the screening of high-risk population in high-risk areas should be changed into the opportunistic screening in primary medical institutions. The opportunistic screening could expand the coverage of the screening, early diagnosis and early treatment project of the upper gastrointestinal cancer, and increase the early diagnosis rate in rural areas and primary medical institutions, which could improve the 5-year survival rate of patients with the upper gastrointestinal cancer, and then achieve the sustainable development of the cancer prevention and treatment in China.


Asunto(s)
Detección Precoz del Cáncer , Neoplasias Gastrointestinales/diagnóstico , Neoplasias Gastrointestinales/terapia , Tamizaje Masivo/métodos , China , Endoscopía , Neoplasias Esofágicas/diagnóstico , Neoplasias Esofágicas/etnología , Humanos , Tamizaje Masivo/tendencias , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/etnología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...